Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

3.15USD
23 Feb 2017
Change (% chg)

$0.05 (+1.61%)
Prev Close
$3.10
Open
$3.05
Day's High
$3.17
Day's Low
$3.05
Volume
92,921
Avg. Vol
420,317
52-wk High
$5.59
52-wk Low
$2.35

Select another date:

Mon, Feb 13 2017

BRIEF-Aeterna Zentaris to pursue FDA registration of Macrilen

* Aeterna Zentaris announces plans to pursue FDA registration of Macrilen(tm)

BRIEF-Aeterna Zentaris completes Zoptrex(tm) pivotal Phase 3 clinical trial in advanced endometrial cancer

* Aeterna Zentaris announces completion of Zoptrex(TM) pivotal Phase 3 clinical trial in advanced endometrial cancer; expects to report top-line results in April 2017

BRIEF-Aeterna zentaris Q3 loss per share $0.61

* Aeterna Zentaris - believe have funds necessary to complete two pivotal clinical trials, to report top-line results on both, to file a nda for macrilen in first half of 2017

BRIEF-Aeterna Zentaris says announces $7.6 mln registered direct offering

* Aeterna zentaris announces us$7,560,000 registered direct offering of common shares and warrants

BRIEF-Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen

* Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen

BRIEF-Aeterna and Specialised Therapeutics Asia sign exclusive license agreement

* Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand

BRIEF-AEterna Zentaris announces expiration of remaining Series B warrants

* AEterna Zentaris announces expiration of remaining Series B warrants

Select another date:

More From Around the Web